AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03343522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A multimodal exercise training program (aerobic, strength and flexibility exercises) for 6 months (60-min sessions performed 3 times/week with moderate intensity).
Study NCT02001948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg
Study NCT02001948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg
Study NCT02001948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland
Description: electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
Study NCT02001948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous cannulation and premedication
Description: 18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
Study NCT02359305 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen given by IV
Study NCT02359305 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen suppository given rectally
Study NCT02462330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous MSC from bone marrow
Description: After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
Study NCT02462330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: injections of human albumin
Study NCT01543880 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Prescribed at the discretion of the treating physician according to product labelling
Study NCT02506309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOT - inside-out trans-obturator tape/sling
Description: Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
Study NCT02506309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIS - Innovative fixation single incision sling
Description: Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
Study NCT04326998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: solvent
Description: using solvent (GuttaClear) in procedure
Study NCT04326998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-solvent
Description: non-solvent
Study NCT02601495 — intervention group
Intervention type: BEHAVIORAL
Intervention: Women in a court diversion program
Description: Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
Study NCT01076452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Deep Brain Stimulation
Description: The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
Study NCT03865654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Tool
Description: Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
Study NCT01434108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornithine-phenylacetate
Description: Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days.
Study NCT01434108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ornithine-phenylacetate
Description: Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days.
Study NCT03437356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation using CLOSE protocol
Description: 'CLOSE' protocol: Ablation index > 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index > 550 at the anterior wall, and inter-lesion distance \< 6.0mm
Study NCT03437356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Description: During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or \<70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men \< 70 years, Cr \<1.5mg/dl, >70kg, except 80 mg OD if female >70 years or Cr >1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT.
Study NCT02550574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 2-octylcyanoacrylate
Study NCT02550574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 2-octylcyanoacrylate
Study NCT02550574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 5-0 Vicryl Sutures
Study NCT02550574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 5-0 Vicryl Sutures
Study NCT04465409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.
Description: Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
Study NCT00913705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (taxol and carboplatin)
Description: Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
Study NCT00913705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (taxol and carboplatin)
Description: Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
Study NCT00913705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT01781637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: subcutaneous injection
Study NCT01781637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection
Study NCT04353791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OST-122
Description: Active dose
Study NCT04353791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02377622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype AA
Study NCT02377622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype BB
Study NCT02377622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX CorDiax 80 Dialyzer
Study NCT02377622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX CorDiax 800 Dialyzer
Study NCT02060110 — intervention group
Intervention type: DEVICE
Intervention: Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study
Study NCT02060110 — intervention group
Intervention type: DEVICE
Intervention: MADIT-CRT ICD ONLY ARM
Study NCT02352298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dario Blood Glucose Monitoring System
Description: Fingerstick to obtain blood sample for analysis with the Dario BGMS
Study NCT02352298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: YSI Analyzer
Description: Fingerstick to obtain blood sample for analysis with YSI
Study NCT03682562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Integrity Index
Description: This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones.
Study NCT04526210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
Study NCT04526210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride
Description: Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
Study NCT04191980 — intervention group
Intervention type: OTHER
Intervention: Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists
Description: The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~* Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~* General Hausdorff distance (HD)~* 95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~* 95% HD modified (HD95_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~* Dice coefficient~* Difference in volumes
Study NCT02835261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
Study NCT02017964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02017964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Optional ancillary studies
Study NCT02017964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02017964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02017964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02017964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT02017964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01408199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
Study NCT00352690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel poliglumex
Study NCT00352690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex
Study NCT00352690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Study NCT00352690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00352690 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External beam radiation therapy
Study NCT00352690 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Study NCT03336411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
Study NCT03336411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized mHealth
Description: Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
Study NCT01848301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: OCT imaging of the LAD coronary artery
Study NCT01848301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Infusion in the coronary artery to study endothelial function
Study NCT01848301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial Artery Flow Mediated Dilation
Description: Assess peripheral brachial artery endothelial function
Study NCT01509300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: On days -10 to -9
Study NCT01509300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 4 and continuing until blood counts recover
Study NCT01509300 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 2Gy D-6 to D-4
Study NCT01509300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/M2 once daily IV on days -8 to -4
Study NCT01509300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg IV on day-3 and -2
Study NCT01509300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: begin on 0
Study NCT01509300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: begin on 0
Study NCT01509300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 on day +21
Study NCT02324803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: continuous treatment of 800 mg pazopanib once daily until disease progression
Study NCT04549844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
Study NCT04549844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
Study NCT02865538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080
Study NCT02865538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for BAY3427080)
Study NCT04008784 — intervention group
Intervention type: DRUG
Intervention: Crisaborole 2% Topical Application Ointment [EUCRISA]
Description: Ointment
Study NCT04008784 — intervention group
Intervention type: DRUG
Intervention: Triamcinolone Acetonide 0.1% Ointment
Description: Topical Corticosteroid
Study NCT04709809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retinal Vessel Analyzer recordings with electrocardiographic (ECG) gating
Description: Video recordings of ocular fundus, an analysis of dynamic vessel diameters and putting them in ECG context.
Study NCT03986177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Intervention Package
Description: Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~* Interactive education and support on use of an asthma action plan~* Locally adapted patient-provider communication tool~* Child-oriented educational materials in comic book format~* Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~* Education regarding environmental trigger abatement~* Patient navigation, home visits, and goal setting support from nurse manager
Study NCT03960970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: Additional IV Azithromycin 500 mg to Standard Prophylaxis
Study NCT03960970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefoxin 2g
Description: Standard Prophylaxis
Study NCT03960970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefoxin 2g
Description: Standard Prophylaxis
Study NCT02539589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BART
Description: BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
Study NCT02539589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
Study NCT04335578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zampilimab
Description: Participants will receive zampilimab (UCB7858) at pre-specified time-points.
Study NCT04335578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo (PBO) at pre-specified time-points.
Study NCT03309709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous progesterone
Description: 25mg daily for 7 days
Study NCT01900730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
Study NCT01900730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA)
Description: Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
Study NCT01900730 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline, weeks 2, 6, and 10.
Study NCT01900730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, weeks 2, 6, and 10.
Study NCT01900730 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pill Diary
Description: Patient given a pill diary to record the time each dose taken.